Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction

BACKGROUND: Recent evidence suggests that the mineralocorticoid receptor antagonist spironolactone should be the preferred fourth-line antihypertensive treatment in resistant hypertension (RHTN). Whether spironolactone improves blood pressure (BP) control in heart failure with preserved ejection fra...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am J Hypertens
Glavni autori: Rossignol, Patrick, Claggett, Brian Lee, Liu, Jiankang, Vardeny, Orly, Pitt, Bertram, Zannad, Faiez, Solomon, Scott
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Original Contributions
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5861580/
https://ncbi.nlm.nih.gov/pubmed/29228101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ajh/hpx210
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items